Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Jeffrey L. Vacirca
88 Eflapegrastim, a Long-Acting Granulocyte Colony-Stimulating Factor, Administered the Same Day as Chemotherapy in Patients With Early-Stage Breast Cancer: Results From a Multicenter, Open-Label Study
Background Patients with early-stage breast cancer receiving docetaxel and cyclophosphamide chemotherapy have a risk of severe neutropenia and febrile neutropenia. The National Comprehensive Cancer Network recommends GCSF to reduce the risk of febrile neutropenia. Eflapegrastim—a novel, long-acting, recombinant human GCSF linked to human IgG4 Fc fragment—showed improved bone marrow residence vs pegfilgrastim that may allow for same-day dosing.
Can "Antagonism" Between Community Oncology Practices and Hospitals Be Overcome?
"I think there's always going to be some degree of antagonism between hospital-based practices and community-based practices," says Jeffrey Vacirca, MD, a medical oncologist and the CEO of New York Cancer and Blood Specialists. Despite this inherent friction, Dr. Vacirca explained why collaborations between these different types of practices can be so beneficial for patients during the Community Oncology Alliance (COA) 2024 Community Oncology Conference.
“It’s crazy money”: PBMs and the Need for Transparency
Jeffrey Vacirca, MD, CEO of New York Cancer & Blood Specialists and OneOncology, said transparency is the number one need when it comes to dealing with pharmacy benefit managers. “No one knows where the money goes. No one knows how much money it is.” He also talks with OBR Oncology about why his group is likely to pass on the new Enhancing Oncology Model (EOM) and why he thinks consolidation is so critical for community oncology.
Op Ed: The Hidden Middlemen Increasing Costs of Your Prescription Drugs
Politicians make easy headlines blaming drug companies for the high drug prices. After all, drug makers are easy targets and certainly share the blame. However, missing from the headlines are even bigger villains called “pharmacy benefit managers” or PBMs who fuel drug prices higher and get in the way of cancer patients receiving critical treatments.
The Trump administration’s absurd devaluing of cancer care for seniors
Let me take you into my exam room when I had to give my 75-year-old patient, “Mrs. Simpson” (a real patient’s case but using a pseudonym for privacy), the terrible news that she has multiple myeloma. Her case underscores the absurdity of the Trump administration’s recent proposal to pay the same amount to providers to evaluate and manage a patient with the sniffles, as they would to manage Mrs. Simpson’s complicated cancer.
Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetron
J Vacirca reports stock ownership from Odonate Therapeutics, and has been a consultant/advisor for Heron Therapeutics and ION. D Caruana is employed by North Shore Hematology/Oncology Associates, PC, a division of New York Cancer & Blood Specialists, and has received compensation for travel and accommodations from Oncopeptides AB. G Calcanes is employed and has a leadership role at North Shore Hematology/Oncology Associates, PC, a division of New York Cancer & Blood Specialists.
Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetron
Aim: This retrospective analysis evaluated chemotherapy-induced nausea and vomiting (CINV)-related hydration needs with palonosetron or granisetron extended-release subcutaneous (GERSC), approved in 2016 for CINV prevention.
A Medicare Experiment With a Grim Prognosis
Federal bureaucrats announced earlier this year that they plan to upend the way Medicare Part B pays for drugs. The goal? To save money by getting doctors to alter their treatment choices. That’s bad medicine, flawed economics and destructive public policy—and Congress should pass legislation to stop this ill-conceived experiment. Medicare plays a crucial role in the lives of more than 55 million Americans. It is the only way some seniors can get access to the drugs that keep them alive.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Jeffrey L.
Contact Jeffrey L., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack